Literature DB >> 17557890

Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients.

L Teixeira1, L Mouthon, A Mahr, A Berezné, C Agard, M Mehrenberger, L-H Noël, P Trolliet, C Frances, J Cabane, L Guillevin.   

Abstract

OBJECTIVES: To describe presentation and outcome of patients with scleroderma renal crisis (SRC).
METHODS: SRC was defined as rapidly progressive oliguric renal insufficiency and/or rapidly progressive arterial hypertension occurring during the course of systemic sclerosis (SSc). Chronic dialysis-free survival was analysed using multivariate Cox proportional hazards regression models. The risk for developing SRC associated with corticosteroid (CS) exposure during the preceding 1- or 3-month periods was analysed according to a case-crossover design.
RESULTS: A total of 50 SSc patients aged 53.3 (14.5) (mean (SD)) years were included in the study. SRC occurred between 1979 and 2003, after a mean (SD) disease duration of 27.7 (49.1) months. A total of 43 (86%) patients had diffuse SSc, 5 (10%) had limited cutaneous SSc and 2 (4%) had SSc sine scleroderma. At the time of SRC, 10 (20%) patients were taking angiotensin converting enzyme inhibitors, and mean creatininaemia was 468 (293) micromol/l. A total of 28 (56%) patients required haemodialysis. In all, 11 patients underwent a renal biopsy, all of them had specific vascular lesions of SRC. Multivariate analyses retained age >53 years and normal blood pressure as independent predictors of decreased dialysis-free survival. Exposure to CS prior to SRC was identified in 30 (60%) patients. The odds ratios for developing SRC associated with CS exposure during the preceding 1- or 3-month periods were 24.1 (95% CI 3.0-193.8) and 17.4 (95% CI 2.1-144.0), respectively.
CONCLUSION: SRC remains associated with severe morbidity and mortality. CS might increase the risk of developing SRC. Further studies are needed to confirm these results.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17557890     DOI: 10.1136/ard.2006.066985

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  53 in total

1.  Steroid-induced scleroderma renal crisis in an at-risk patient.

Authors:  Sebastian Miguel Toescu; Alex Mansell; Eoin Dinneen; Malcolm Persey
Journal:  BMJ Case Rep       Date:  2014-11-13

Review 2.  Evidence-based management of rapidly progressing systemic sclerosis.

Authors:  Dinesh Khanna; Christopher P Denton
Journal:  Best Pract Res Clin Rheumatol       Date:  2010-06       Impact factor: 4.098

3.  HLA-DRB1*0407 and *1304 are risk factors for scleroderma renal crisis.

Authors:  Binh Nguyen; Maureen D Mayes; Frank C Arnett; Deborah del Junco; John D Reveille; Emilio B Gonzalez; Hilda T Draeger; Marilyn Perry; Amir Hendiani; Kiran K Anand; Shervin Assassi
Journal:  Arthritis Rheum       Date:  2011-02

4.  Tc-99m diethylenetriamine pentaacetic acid (DTPA) renal function reserve estimation: is it a reliable predictive tool for assessment of preclinical renal involvement in scleroderma patients?

Authors:  Amr Amin; S El-Sayed; N Taher; M Sedki; H Nasr
Journal:  Clin Rheumatol       Date:  2012-02-24       Impact factor: 2.980

Review 5.  Scleroderma renal crisis: a rare but severe complication of systemic sclerosis.

Authors:  Luc Mouthon; Alice Bérezné; Guillaume Bussone; Laure-Hélène Noël; Peter M Villiger; Loïc Guillevin
Journal:  Clin Rev Allergy Immunol       Date:  2011-04       Impact factor: 8.667

Review 6.  Scleroderma lung disease.

Authors:  Joshua J Solomon; Amy L Olson; Aryeh Fischer; Todd Bull; Kevin K Brown; Ganesh Raghu
Journal:  Eur Respir Rev       Date:  2013-03-01

7.  An International, Web-Based, Prospective Cohort Study to Determine Whether the Use of ACE Inhibitors prior to the Onset of Scleroderma Renal Crisis Is Associated with Worse Outcomes-Methodology and Preliminary Results.

Authors:  Marie Hudson; Murray Baron; Ernest Lo; Joanna Weinfeld; Daniel E Furst; Dinesh Khanna
Journal:  Int J Rheumatol       Date:  2010-09-14

8.  Renal manifestations in scleroderma: evidence for subclinical renal disease as a marker of vasculopathy.

Authors:  Victoria K Shanmugam; Virginia D Steen
Journal:  Int J Rheumatol       Date:  2010-08-17

Review 9.  Determinants of mortality in systemic sclerosis: a focused review.

Authors:  Dilli Ram Poudel; Divya Jayakumar; Abhijeet Danve; Shiv Tej Sehra; Chris T Derk
Journal:  Rheumatol Int       Date:  2017-11-07       Impact factor: 2.631

Review 10.  A "silent" course of normotensive scleroderma renal crisis: case report and review of the literature.

Authors:  Hadim Akoglu; Gokhan Kadir Atilgan; Ramazan Ozturk; Ezgi Coskun Yenigun; Ipek Isik Gonul; Ali Riza Odabas
Journal:  Rheumatol Int       Date:  2008-12-02       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.